Browse investments

Invest in Sight Sciences Inc on Stash

Sight Sciences, Inc. is an ophthalmic medical device company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company’s surgical glaucoma product portfolio features the OMNI surgical system (OMNI), a device that facilitates the performance of both trabeculotomy and canaloplasty with a single device and single corneal incision. Its nonsurgical dry eye product portfolio consists of the TearCare system for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids. The Company has two reportable segments: Surgical Glaucoma and Dry Eye. Its Surgical Glaucoma segment consists of sales of the OMNI surgical system. Its Dry Eye segment includes sales of the TearCare system and related components and accessories. The Company primarily sell both the systems through a direct sales model.

To buy fractional shares of Sight Sciences Inc stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Ticker: SGHT

Sight Sciences Inc

$8.28

-0.24%

(1W)

$

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by Thomson Reuters (Refinitiv). ©2024 Thomson Reuters. Stash cannot and does not represent or guarantee that any of the information available via Refinitiv is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

SGHT Performance Breakdown

Share Price

$8.28

Today's change

-2.13%

Year to date change (YTD)

131.28%

Dividend yield

0.0

Last dividend paid

N/A

Last dividend pay date

N/A

About SGHT

Sight Sciences, Inc. is an ophthalmic medical device company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company’s surgical glaucoma product portfolio features the OMNI surgical system (OMNI), a device that facilitates the performance of both trabeculotomy and canaloplasty with a single device and single corneal incision. Its nonsurgical dry eye product portfolio consists of the TearCare system for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids. The Company has two reportable segments: Surgical Glaucoma and Dry Eye. Its Surgical Glaucoma segment consists of sales of the OMNI surgical system. Its Dry Eye segment includes sales of the TearCare system and related components and accessories. The Company primarily sell both the systems through a direct sales model.

Sight Sciences Inc Stock Ticker

SGHT

For more information

https://www.sightsciences.com/

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by Thomson Reuters (Refinitiv). ©2024 Thomson Reuters. Stash cannot and does not represent or guarantee that any of the information available via Refinitiv is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

Invest in Sight Sciences Inc on Stash

Sight Sciences, Inc. is an ophthalmic medical device company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company’s surgical glaucoma product portfolio features the OMNI surgical system (OMNI), a device that facilitates the performance of both trabeculotomy and canaloplasty with a single device and single corneal incision. Its nonsurgical dry eye product portfolio consists of the TearCare system for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids. The Company has two reportable segments: Surgical Glaucoma and Dry Eye. Its Surgical Glaucoma segment consists of sales of the OMNI surgical system. Its Dry Eye segment includes sales of the TearCare system and related components and accessories. The Company primarily sell both the systems through a direct sales model.

To buy fractional shares of Sight Sciences Inc stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Certain companies are volatile

Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.

Sight Sciences Inc stock news

24/7 Wall Street

Oracle Plunges 12% Despite Earnings Beat as $50 Billion Spending Plan Stuns Investors

Yesterday we highlighted Oracle's massive $455 billion cloud backlog and the question of whether infrastructure spending would finally convert to sustainable margin expansion.

about 8 hours ago

CNBC

The Fed's hawkish cut, Oracle earnings, Coca-Cola's next CEO and more in Morning Squawk

The Federal Reserve cut interest rates by 25 basis points but struck a hawkish tone. Shares of Oracle dropped after the company missed Wall Street's revenue expectations.

about 8 hours ago

Business Insider

Warren Buffett hired Todd Combs to take over Berkshire's portfolio one day. Here's what close watchers say about his surprise exit.

Warren Buffett hired Todd Combs to eventually succeed him as Berkshire Hathaway's stock picker. Combs, one of Buffett's two investment managers and Geico's CEO, has quit to join JPMorgan.

about 10 hours ago

24/7 Wall Street

Fast-Casual Darling Grows Revenue 20% but Profit Margins Tell a Different Story

CAVA Group (NYSE: CAVA) and Chipotle Mexican Grill (NYSE: CMG) both reported Q3 2025 earnings in late October and early November.

about 8 hours ago

Why invest with Stash?

Fractional shares

Thousands of stocks and ETFs. No investing minimums.

Unlimited trades

Plus no add-on trading commission fees.^†

Diversification analysis

Custom investment recommendations can help you diversify.

Automatic investing

Dividend reinvestment,⁸ recurring investments, and more.

The Stock-Back® Card

We’ll give you matching stock in companies you shop at.¹

Learn how to invest

Get professional advice and education at every step.

How to buy Sight Sciences Inc stock on Stash

Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.

Sight Sciences Inc’s share price is determined by its bid-ask spread, which is the difference between the price that buyers are willing to pay and the price that sellers are willing to accept. Sight Sciences Inc’s price can fluctuate throughout the course of each trading day—when you buy Sight Sciences Inc through Stash, we execute the market order during our next available trading window (we have two a day). At Stash, we don’t recommend trying to predict the market when buying investments. We believe it can be a better strategy to buy quality investments you believe in, then hang onto them.

Use our historic performance chart to see real-time Sight Sciences Inc stock price and the Sight Sciences Inc news feed to help further your research before investing in fractional shares with any dollar amount you choose.

Stash offers two subscription plans: Stash Growth and Stash+.

Each plan can help you reach different goals and offers a unique combination of financial accounts and features. All plans include access to a personal brokerage account—also known as your personal investment account. You can use your Stash personal portfolio to purchase any of the available investments on our platform, as well as access our suite of automatic saving and investing tools. Learn more about Stash pricing.

Once your market order of Sight Sciences Inc stock is complete, you'll officially be a shareholder of Sight Sciences Inc!